Back to Browse Journals » Vascular Health and Risk Management » Volume 5

The management of gestational diabetes

Authors N Wah Cheung

Published Date January 2009 Volume 2009:5 Pages 153—164

DOI http://dx.doi.org/10.2147/VHRM.S3405

Published 15 January 2009

N Wah Cheung

Centre for Diabetes and Endocrinology Research, Westmead Hospital, and University of Sydney, NSW, Australia

Abstract: The incidence of gestational diabetes is increasing. As gestational diabetes is associated with adverse pregnancy outcomes, and has long-term implications for both mother and child, it is important that it is recognized and appropriately managed. This review will examine the pharmacological options for the management of gestational diabetes, as well as the evidence for blood glucose monitoring, dietary and exercise therapy. The medical management of gestational diabetes is still evolving, and recent randomized controlled trials have added considerably to our knowledge in this area. As insulin therapy is effective and safe, it is considered the gold standard of pharmacotherapy for gestational diabetes, against which other treatments have been compared. The current experience is that the short acting insulin analogs lispro and aspart are safe, but there are only limited data to support the use of long acting insulin analogs. There are randomized controlled trials which have demonstrated efficacy of the oral agents glyburide and metformin. Whilst short-term data have not demonstrated adverse effects of glyburide and metformin on the fetus, and they are increasingly being used in pregnancy, there remain long-term concerns regarding their potential for harm.

Keywords: gestational diabetes, insulin, oral antidiabetic agents, pregnancy, type 2 diabetes

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells [Corrigendum]

Yu L, Wang XL, Zhu D, Ding WC, Wang LM, Zhang CL, Jiang XH, Shen H, Liao SJ, Ma D, Hu Z, Wang H

OncoTargets and Therapy 2015, 8:365-366

Published Date: 4 February 2015

Maternal and neonatal tetanus elimination: from protecting women and newborns to protecting all

Khan R, Vandelaer J, Yakubu A, Raza AA, Zulu F

International Journal of Women's Health 2015, 7:171-180

Published Date: 3 February 2015

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Eickels MV, Turpie AGG

Vascular Health and Risk Management 2014, 10:425-434

Published Date: 17 July 2014

Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?

Mahabala C, Kamath P, Bhaskaran U, Pai ND, Pai AU

Vascular Health and Risk Management 2013, 9:125-133

Published Date: 24 March 2013

Corrigendum

De Caterina AR, Harper AR, Cuculi F

Vascular Health and Risk Management 2012, 8:443-445

Published Date: 19 July 2012

Cardiovascular disease in patients with chronic kidney disease

Julian Wright, Alastair Hutchison

Vascular Health and Risk Management 2009, 5:713-722

Published Date: 26 August 2009

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009